Innovative adhesive free woundcare solutions, transforming hidradenitis suppurativa & chronic wound care
Business overview
Location | Dublin 15, Ireland |
---|---|
Social media | |
Website | www.hidramedsolutions.com |
Sectors | Healthcare Non-Digital B2B |
Company number | 581597 |
Incorporation date | 28 Apr 2016 |
Investment summary
Business highlights
- Transforming chronic wound care
- Innovating adhesive-free dressings
- Empowering patients, changing lives
- Leading in global HS wound management
Key features
Idea
Introduction
HidraMed Solutions, a pioneering patient-founded company, is revolutionising chronic wound care with its patented HidraWear range, a truely disruptive adhesive-free wound care technology designed for people suffering from wounds in flexural and friable skin areas, i.e the buttocks, groin, and armpits, which are difficult to dress. Damage to skin from adhesive dressings cause secondary wounds and prevent wounds from healing, posing substantial challenges to patients and clinicians alike, causing unnecessary pain, skin stripping, maceration, blistering and skin tears.
HidraWear offers clinically proven improved comfort, flexibility, and ease of use compared to traditional wound care methods, greatly enhancing the quality of life for those with HS. This innovation represents a significant step forward in addressing the needs of a patient groups that have historically had limited options for effective wound management. It's simple, it's easy to use, and it works.
Monetisation strategy
Fully reimbursed in our major markets, HidraWear is prescribable, widely covered by insurance in the USA, and supported by the NHS in the UK. Its successful market launches have established HidraWear as one of the fastest-growing superabsorbers in the UK.
Direct patient engagement, via education, social media supports patients into the reimbursed system in our key markets, via prescription in the UK and the USA. Direct sales into the hospital and community channel provide access in the accute and community markets.
In 2023, HidraMed Solutions achieved revenues of over €400K with a modest sales & commercialisation team (based on unaudited management accounts). The main activity for Revenue growth came from the UK and US prescription sales.
Supporting our key sales and distribution partners like Daylong (UK), Rotech (US), Prism (US) and Cardinal Health (US), is paramount to build on our successful implementation of our commercialsation strategy to date and to realise the anticpated revenue growth through 2024 & 2025
Open an account to get access to more details about the Hidramed Solutions campaign
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Open an account to get access to more details about the Hidramed Solutions campaign
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Open an account to get access to the team members of Hidramed Solutions
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Open an account to get access to the Hidramed Solutions campaign updates
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Open an account to get access to the list of investors in the Hidramed Solutions campaign
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Open an account and verify your identity to get access to the Hidramed Solutions discussion
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Open an account and verify your identity to get access to the Hidramed Solutions pitch deck and other documents
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.